{"log_id": 1711047783124603466, "direction": 0, "words_result_num": 46, "words_result": [{"probability": {"variance": 0.021459, "average": 0.930782, "min": 0.403681}, "location": {"width": 757, "top": 148, "height": 36, "left": 210}, "words": "为35岁(16—66岁),75%为男性,其中16%的患者曾接受过a一千扰治疗治疗前"}, {"probability": {"variance": 0.0223, "average": 0.910561, "min": 0.433713}, "location": {"width": 767, "top": 188, "height": 35, "left": 208}, "words": "患者平均血清 HBV DNA基线水平为8.821Og拷贝/mL(PCR法),平均血清ALT基线水平为"}, {"probability": {"variance": 0.01015, "average": 0.946949, "min": 0.617325}, "location": {"width": 764, "top": 228, "height": 34, "left": 208}, "words": "8U/L,且有89%的患者为 IIBCAG阳性。恩替卡韦在主要疗效终点(第12周 IIBV DNA水平"}, {"probability": {"variance": 0.006034, "average": 0.972397, "min": 0.58239}, "location": {"width": 672, "top": 267, "height": 36, "left": 206}, "words": "较基线的平均变化值,PCR法)优于安慰剂。生化、病毒学和血清学结果见表2"}, {"probability": {"variance": 0.008635, "average": 0.95544, "min": 0.634036}, "location": {"width": 674, "top": 332, "height": 36, "left": 205}, "words": "表2:拉米夫定治疗尖效患者试验第12周的生化、病毒学和血清学结果(AI46"}, {"probability": {"variance": 0, "average": 0.992799, "min": 0.992799}, "location": {"width": 28, "top": 338, "height": 25, "left": 1091}, "words": "证"}, {"probability": {"variance": 0.001353, "average": 0.975745, "min": 0.859142}, "location": {"width": 224, "top": 378, "height": 24, "left": 445}, "words": "恩替卡韦1.0mg安慰剂"}, {"probability": {"variance": 0.062859, "average": 0.745259, "min": 0.494542}, "location": {"width": 43, "top": 376, "height": 23, "left": 773}, "words": "差值"}, {"probability": {"variance": 0.000392, "average": 0.982583, "min": 0.944519}, "location": {"width": 45, "top": 409, "height": 19, "left": 443}, "words": "N=105"}, {"probability": {"variance": 7e-06, "average": 0.981984, "min": 0.979023}, "location": {"width": 40, "top": 408, "height": 18, "left": 603}, "words": "N28"}, {"probability": {"variance": 0.019675, "average": 0.912249, "min": 0.565091}, "location": {"width": 170, "top": 400, "height": 24, "left": 774}, "words": "恩替卡韦一安慰剂"}, {"probability": {"variance": 0.001366, "average": 0.97141, "min": 0.886393}, "location": {"width": 160, "top": 428, "height": 23, "left": 777}, "words": "(5%可信区间)P值"}, {"probability": {"variance": 0, "average": 0.997463, "min": 0.997463}, "location": {"width": 22, "top": 463, "height": 22, "left": 247}, "words": " NA"}, {"probability": {"variance": 0.000236, "average": 0.978877, "min": 0.958535}, "location": {"width": 45, "top": 461, "height": 20, "left": 446}, "words": "4.31"}, {"probability": {"variance": 0.002181, "average": 0.933082, "min": 0.871949}, "location": {"width": 47, "top": 457, "height": 23, "left": 608}, "words": "0.17"}, {"probability": {"variance": 0.006087, "average": 0.96755, "min": 0.667447}, "location": {"width": 168, "top": 454, "height": 23, "left": 789}, "words": "4.04(-4.54,-3.54)"}, {"probability": {"variance": 0.000442, "average": 0.977088, "min": 0.945448}, "location": {"width": 179, "top": 486, "height": 25, "left": 246}, "words": " BV DNA较基线值的平"}, {"probability": {"variance": 0.004417, "average": 0.961587, "min": 0.786342}, "location": {"width": 79, "top": 483, "height": 21, "left": 771}, "words": "p<0.0001"}, {"probability": {"variance": 0.01917, "average": 0.944827, "min": 0.531096}, "location": {"width": 189, "top": 515, "height": 24, "left": 236}, "words": "均变化值(log拷贝"}, {"probability": {"variance": 0.000772, "average": 0.976389, "min": 0.905187}, "location": {"width": 123, "top": 544, "height": 21, "left": 237}, "words": "/L)(PCR法)"}, {"probability": {"variance": 0.039746, "average": 0.776412, "min": 0.479425}, "location": {"width": 235, "top": 568, "height": 25, "left": 237}, "words": " HBY DNA<O. 7MCU/ml 718"}, {"probability": {"variance": 0.00055, "average": 0.982091, "min": 0.927159}, "location": {"width": 147, "top": 561, "height": 24, "left": 769}, "words": "60.4(39.9,81.0)"}, {"probability": {"variance": 0.027212, "average": 0.923294, "min": 0.519394}, "location": {"width": 84, "top": 595, "height": 22, "left": 265}, "words": "bDNA法“)"}, {"probability": {"variance": 0.003138, "average": 0.956665, "min": 0.846745}, "location": {"width": 76, "top": 590, "height": 20, "left": 768}, "words": "P<0.0001"}, {"probability": {"variance": 0.025969, "average": 0.884483, "min": 0.482532}, "location": {"width": 179, "top": 622, "height": 23, "left": 195}, "words": "ALT复常(≤1XULN)"}, {"probability": {"variance": 0.001633, "average": 0.955091, "min": 0.89987}, "location": {"width": 28, "top": 621, "height": 20, "left": 441}, "words": "68%"}, {"probability": {"variance": 0.011821, "average": 0.948139, "min": 0.57152}, "location": {"width": 146, "top": 613, "height": 22, "left": 769}, "words": "61.3(32.7,89.8)"}, {"probability": {"variance": 0.002445, "average": 0.975, "min": 0.757175}, "location": {"width": 532, "top": 665, "height": 37, "left": 200}, "words": "差值基于基线 HBV DNA水平(PCR法)校正后的线形回归模型"}, {"probability": {"variance": 0.030813, "average": 0.916979, "min": 0.42217}, "location": {"width": 311, "top": 708, "height": 32, "left": 200}, "words": "在基线 HBV DNA≥0.7ME/mLl的患者"}, {"probability": {"variance": 0.018901, "average": 0.927775, "min": 0.475358}, "location": {"width": 225, "top": 750, "height": 29, "left": 200}, "words": "在基线ALT>1XUN的患者"}, {"probability": {"variance": 0.014736, "average": 0.932756, "min": 0.488121}, "location": {"width": 732, "top": 806, "height": 37, "left": 233}, "words": "服用本品1.0mng/天,特续48周(12周的双窗给药加上36周的开放期给药),能够非"}, {"probability": {"variance": 0.001065, "average": 0.983852, "min": 0.869548}, "location": {"width": 765, "top": 842, "height": 41, "left": 188}, "words": "常有效地降低拉米夫定治疗失效患者的 HBV DNA水平基线时ALT水平异常的患者经治疗后"}, {"probability": {"variance": 0.010847, "average": 0.956661, "min": 0.487912}, "location": {"width": 764, "top": 882, "height": 40, "left": 188}, "words": "85%患者ALT水平复常。在双富阶段服用安慰剂的患者转为思替卡韦开放给药(1.0mg/天"}, {"probability": {"variance": 0.000699, "average": 0.975138, "min": 0.91983}, "location": {"width": 164, "top": 933, "height": 25, "left": 187}, "words": "36周),疗效相同"}, {"probability": {"variance": 0.000296, "average": 0.987984, "min": 0.955426}, "location": {"width": 117, "top": 999, "height": 26, "left": 185}, "words": "国外临试验"}, {"probability": {"variance": 0.003011, "average": 0.977044, "min": 0.723035}, "location": {"width": 709, "top": 1025, "height": 39, "left": 228}, "words": "在五大洲进行的3个设立阳性对照的期试验中评价了恩替卡节的安全性和有效性"}, {"probability": {"variance": 0.006776, "average": 0.964638, "min": 0.620556}, "location": {"width": 775, "top": 1064, "height": 39, "left": 183}, "words": "这些研究包含1633名16岁或以上的慢性乙肝病毒感染(持续6个月血清乙肝病毒表面抗原"}, {"probability": {"variance": 0.026842, "average": 0.896853, "min": 0.422949}, "location": {"width": 772, "top": 1101, "height": 42, "left": 185}, "words": "量阳性)同时检测到病毒复制(用N杂变或PCR方法检测到血清 HIBV. DNA)的患者。受"}, {"probability": {"variance": 0.008147, "average": 0.948739, "min": 0.694138}, "location": {"width": 774, "top": 1139, "height": 44, "left": 184}, "words": "试者的入选标准为:持续增加的高于正常水平上(ULN1.3倍的AT水平和肝活组织"}, {"probability": {"variance": 0.027096, "average": 0.908011, "min": 0.410484}, "location": {"width": 776, "top": 1178, "height": 44, "left": 180}, "words": "检查提示有慢性病毒性肝炎在6名合染IBY租IV患者的研究中也评价了替卡韦"}, {"probability": {"variance": 0.002296, "average": 0.973293, "min": 0.849882}, "location": {"width": 158, "top": 1231, "height": 26, "left": 180}, "words": "的安全性和有效性"}, {"probability": {"variance": 0.000198, "average": 0.989207, "min": 0.94562}, "location": {"width": 309, "top": 1291, "height": 35, "left": 178}, "words": "核苷类药物初治患者(肝功能代偿)"}, {"probability": {"variance": 0.019437, "average": 0.930791, "min": 0.465286}, "location": {"width": 770, "top": 1322, "height": 41, "left": 185}, "words": "HAg:AI463022号研究是一个多国家的、随机双盲的研究。研究在709名患者(715"}, {"probability": {"variance": 0.00415, "average": 0.972047, "min": 0.677218}, "location": {"width": 776, "top": 1359, "height": 42, "left": 179}, "words": "名随机)中进行,他们均为核苷类药物初治的使性乙肝病毒感染且 libeag阳性患者,分别采"}, {"probability": {"variance": 0.010534, "average": 0.945758, "min": 0.603703}, "location": {"width": 775, "top": 1397, "height": 42, "left": 177}, "words": "用每日一次服用0.5mg思替卡韦和100mg拉米夫定进行治疗,持续52周。患者的平均年龄"}, {"probability": {"variance": 0.019404, "average": 0.923896, "min": 0.422031}, "location": {"width": 779, "top": 1434, "height": 41, "left": 177}, "words": "为35岁(1678岁),75%患者为男性,57%为亚洲人,40%为欧洲人,13%曾接受v干扰素"}], "language": 3}